Author Question: A score of 9 on a biophysical profile is considered: a. Abnormal. b. Equivocal. c. Normal. d. ... (Read 223 times)

naturalchemist

  • Hero Member
  • *****
  • Posts: 542
A score of 9 on a biophysical profile is considered:
 
  a. Abnormal.
  b. Equivocal.
  c. Normal.
  d. None of the above.

Question 2

A newborn who is large for gestational age (LGA) is __________ percentile(s) for weight.
 
  a. Below the 90th
  b. Less than the 10th
  c. Greater than the 90th
  d. Between the 10th and 90th



yeungji

  • Sr. Member
  • ****
  • Posts: 319
Answer to Question 1

C
Five parameters of fetal activity (fetal heart rate, fetal breathing movements, gross fetal movements, fetal tone, and amniotic fluid volume) are used to determine the biophysical profile. The maximum score is 2 points for each parameter. A score falling between 8 and 10 is considered normal.
A score of 4 or less is considered abnormal.
A score of 9 is considered reassuring.
A score of 8 to 10 is considered reassuring.

Answer to Question 2

C
The LGA rating is based on weight and is defined as greater than the 90th percentile in weight.
An infant between the 10th and 90th percentiles is average for gestational age.
An infant in less than the 10th percentile is small for gestational age.
This infant is considered average for gestational age.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question

yeungji

  • Sr. Member
  • ****
  • Posts: 319

 

Did you know?

Human kidneys will clean about 1 million gallons of blood in an average lifetime.

Did you know?

Medications that are definitely not safe to take when breastfeeding include radioactive drugs, antimetabolites, some cancer (chemotherapy) agents, bromocriptine, ergotamine, methotrexate, and cyclosporine.

Did you know?

More than 150,000 Americans killed by cardiovascular disease are younger than the age of 65 years.

Did you know?

Approximately 500,000 babies are born each year in the United States to teenage mothers.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library